UniProtKB/Swiss-Prot Q5T0T0: Variant p.Pro92Ser

E3 ubiquitin-protein ligase MARCHF8
Gene: MARCHF8
Feedback?

Variant information Variant position:

92 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Proline (P) to Serine (S) at position 92 (P92S, p.Pro92Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and hydrophobic (P) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs3764990 [ dbSNP | Ensembl ]

Sequence information Variant position:

92 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

291 The length of the canonical sequence.
Location on the sequence:

ITPSSQDICRICHCEGDDES P LITPCHCTGSLHFVHQACLQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ITPSSQDICRICHCEGDDESPLITPCHCTGSLHFVHQACLQ

Mouse                         VTPSNQDICRICHCEGDDESPLITPCHCTGSLHFVHQACLQ

Bovine                        VTPSNQDICRICHCEGDDESPLITPCRCTGSLHFVHQTCLQ

Xenopus laevis                VTPSSQDICRICHCEGDDESPLITPCHCTGSLHFVHQACLQ

Xenopus tropicalis            VTPSSQDICRICHCEGDDESPLITPCHCTGSLHFVHQACLQ

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 291	E3 ubiquitin-protein ligase MARCHF8
Zinc finger	72 – 133	RING-CH-type
Binding site	80 – 80
Binding site	83 – 83
Binding site	97 – 97
Binding site	99 – 99
Binding site	107 – 107
Binding site	110 – 110
Alternative sequence	79 – 79	I -> ICSSSAVFSECCHHSSVQSAVVSKAPHCQSSLTQGLTVTVICKDTLQASKRNSFGSEWAQALKPAKNTKARRTLKFSRSLNDVGEKAQDTSESFAYVERTCSEGKLILPQDTCLRTNRFHHKEKRTLNHKPLGNSKHSCVSCLSAGRSTASEVEAGKGGRPGLLLEEKADGEATSRSRQLLQYLFSLSHGLSASSLHRFHELESCAARLHTAKSSSGLAGSMGFCSDEMGDDDVFEDSTSAKLKSRVLRAPLCSTEKDSDLDCPSPFSEKLPPISPVSTSGDV. In isoform 2.
Mutagenesis	80 – 80	C -> S. Strong loss of catalytic activity; when associated with S-83, S-123 and S-126.
Mutagenesis	83 – 83	C -> S. Strong loss of catalytic activity; when associated with S-80, S-123 and S-126.

Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.